CD4 and myeloid sarcoma: Natalizumab-treated MS patients had significantly decreased expression of the co-stimulatory molecule CD134 on CD4+CD26HIGH T-cells, in blood, and natalizumab decreased the expression of CD134 on MBP-reactive CD26HIGHCD4+ T-cells in vitro.